SCHEMBL23992178

SCHEMBL23992178

NC(=O)C/C=C/c1cccnc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.60
MAPT P10636 2/20 0.57
RAB9A P51151 2/20 0.57
KDM4E B2RXH2 2/20 0.57
NPC1 O15118 1/20 0.57
JUN P05412 1/20 0.57
NFKB1 P19838 1/20 0.57
MAPK1 P28482 1/20 0.57
GPR55 Q9Y2T6 1/20 0.57
CYP2D6 P10635 3/20 0.50
CHRNB2 P17787 2/20 0.50
CHRNA4 P43681 2/20 0.50
KMT2A Q03164 2/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA7 P36544 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
PFKFB3 Q16875 1/20 0.50
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9488251 0.86 MAPT (0.61) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL30227267 0.85 TBXAS1 (0.66) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL868080 0.85 TBXAS1 (0.66) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL868079 0.85 TBXAS1 (0.66) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL17787984 0.83 MAPT (0.62) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL3465670 0.83 MAPT (0.51) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL4592716 0.80 TBXAS1 (0.59) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL10276665 0.80 MAPT (0.53) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL30396999 0.78 MAPT (0.51) TBXAS1MAPTRAB9AKDM4ENPC1
SCHEMBL4201926 0.78 MAPT (0.51) TBXAS1MAPTRAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263790-A1 HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2023-08-24 US disclosed
US-11672788-B2 Histone deacetylase inhibitors for immunomodulation in tumor microenvironment Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2023-06-13 US disclosed
US-20210379032-A1 HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2021-12-09 US disclosed
WO-2021219040-A1 HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT GNT BIOTECH & MEDICALS CORPORATION (CN) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210379032-A1 HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT HDAC1, HDAC2, HDAC9 TBXAS1 2522/4885MAPT 3635/4885RAB9A 2886/4885
US-11672788-B2 Histone deacetylase inhibitors for immunomodulation in tumor microenvironment HDAC1, HDAC2, HDAC9 TBXAS1 2522/4885MAPT 3635/4885RAB9A 2886/4885
US-20230263790-A1 HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT HDAC1, HDAC2, HDAC9 TBXAS1 2522/4885MAPT 3635/4885RAB9A 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.